The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

EU approval granted to Novartis SCEMBLIX for CML

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The European Commission has approved Scemblix (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Phase III PSMAfore trial: Pluvicto demonstrates clinically meaningful rPFS benefit in prostate cancer

In the phase III PSMAfore trial, Pluvicto (lutetium (177Lu) vipivotide tetraxetan) met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer after treatment with androgen receptor pathway inhibitor therapy, compared to a change in ARPI1. 
In Brief

The Max Foundation to make Novartis’s Scemblix available in low- & middle-income countries

The Max Foundation, a global nonprofit organization that aims to accelerate health equity by delivering medication, technology, and supportive services to patients globally, will launch access to the Novartis therapy Scemblix (asciminib) in 36 low- and middle-income countries in 2023 for people living with chronic myeloid leukemia as part of the CancerPath to Care collaboration with Novartis.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account